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Ethical approvals for this study were obtained in countries in which they were required; other countries approved the register for conduct as an anonymized audit. Year of treatment, DNT, and center codes were electronically extracted from the SITS database. We also extracted sex, age, baseline National Institutes of Health Stroke Scale (NIHSS), and history of diabetes mellitus, hypertension, atrial fibrillation, and previous stroke. We then identified the year when centers started registering patients into the SITS registry and looked in detail at those which started in the first 3 On the basis of the retrieved number of patients treated in the centers per year, we created 6 volume/y categories: <5, 5 to 24, 25 to 49, 50 to 74, 75 to 99, and ≥100 treated patients/y. A center was attributed to a volume/y category if it was in the category range at least for 3 subsequent years. We could not analyze the effect of the type of stroke center because primary, secondary, and tertiary stroke centers were not defined in 2002. Hence, each center was judged by how soon it started entering data into the SITS registry and by the number of patients treated annually. The center experience, however, was evaluated by the annual volume of patients and not by the length of SITS membership. The latter does not necessarily reflect the experience because some dedicated stroke centers might have joined the SITS later. Nonetheless, there is one exception. The centers that joined the SITS registry during 2003 can be considered as the most experienced because the European Authorities granted conditional license for stroke thrombolysis with alteplase in 2002. One of the license conditions was that all patients treated with thrombolysis must be registered into the SITS registry; hence, the centers that joined during 2003 (no center joined in 2002) were the centers with experience gained, for example, from the randomized controlled trials. The centers that joined the SITS registry after 2003 implemented the thrombolysis protocol later.
Statistical Analyses
DNT had a non-normal distribution. Temporal changes in DNT among the subsequent years of registration adjusted for the effect of center volume were studied with a model of generalized estimating equations (scale response and γ with log-link model). The model included the following covariates and factors: age, baseline NIHSS, sex, and medical history. About the medical history, the percentages of the missing data were between 1.5% and 2% except for dyslipidemia (10%), which was excluded from the model. The center code was included as a within-subject effect (random) in the generalized estimating equations model; the option for correlation matrix in SPSS was exchangeable. We also included the interaction between center volume and year of treatment in the model. In the simple model, we only tested year of treatment, center volume, NIHSS, and age. Because age was not statistically significant (P=0.76), it was not included in more complex models with comorbidities. Statistical significance was set at 0.05 (2-tailed). Analyses were performed on IBM SPSS 22 (IBM Corp, Armonk, NY).
Results
Between December 2002 and December 2011, 45 079 patients were included in the SITS-ISTR. DNT was not registered for 1.6% (720/45 079) of the patients. These were excluded from the analyses, and the final cohort size was 44 359 patients. Their median DNT was 67 (interquartile range, 47-91) minutes with a mean of 73 (SD, 37) minutes. The overall picture of DNT changes in the whole cohort and by volume category is shown in Figure 1A Table 1 .
The results of the generalized estimating equations model are outlined in Table 2 . After adjustment for sex, NIHSS, and comorbidity, we saw a robust effect on DNT caused by center volume and the enrollment period but a less robust effect of the treatment year (note the differences in both Wald χ 2 and magnitude of β coefficients). The effect estimates are derived using a log-link function. Because of the low number of cases in some of the volume categories (Table 1) , we tested for the sensitivity of our main model (without interaction). For this purpose, we recoded the volume category, so that the largest category was set to >50 patients/y. The results were in line with the original model Table 3 ). Specifically, in these centers, DNT continuously declined until 2008 but then did not significantly change after 2008. For the comparison with the whole cohort (Table 2) (Table 3) , but by including all centers, the change over time is attenuated.
Discussion
Thrombolysis is a complex intervention, which required reorganization of services and specific staff training when it was first introduced. Achievement of fast DNTs is only possible with efficient and well-rehearsed internal processes. It is therefore expected that DTN improves with time as centers gain more experience. However, this study shows that DNT did not change much overall during the first decade of the SITS registry (2002-2011; Figure 1A ). This is in line with the data from Get With The Guidelines program. 9 The observed annual changes in DNT can be better explained by center volume than the year of treatment ( Table 2 ). The most robust annual DNT changes were observed in centers that joined the SITS within the first year (2003; Figure 2 ; Table 3 ). Temporal DNT profile in these centers was different from the whole cohort (Tables 2 and 3) , which suggests that their streamlining of the factors known to be associated with DNT was on a high level. In contrary, in centers that joined the SITS relatively late (after 2009), there were no annual differences in DNT whatsoever. This might suggest that some of the learning from the early adopters was transferred to later registering centers and that the process rather than individual experience is a major factor.
Our observation of patient volume being the strongest determinant of DNT was reported also elsewhere. 9 The effect of volume held true even in centers that joined the SITS registry after 2009. The most robust annual decrease in DNT was observed in centers with high volume of patients (≥100/y and 75-99/y; Tables 2 and 3) even when adjusting for the interaction between center volume and year of treatment (arising (Figures 1 and 2 ). This increase of DNT observed after 2009 can be perhaps explained by publication of the European Cooperative Acute Stroke Study (ECASS)-III trial and SITS-ISTR study at the end of the year 2008, 10,11 which led to extension of the time window for stroke thrombolysis from 3 to 4.5 hours. The implementation of the extended time window followed gradually in different countries and centers. Evidence from UK SITS patients suggests that extension of the time window led to treatment of more patients who may otherwise have missed the window for treatment, but also possibly a relaxation of urgency, 12 which was also shown in our recent analysis. 13 In contrast, Messé et al 14 found that publication of the ECASS-III trial did not lead to longer DNT in Get With The Guidelines.
Taken together, our data confirmed that experience is more robustly linked to high annual volume of patients than to the year of treatment. Such effect of volume is not only unique for stroke thrombolysis 9, 15 but is also seen in other scenarios. [16] [17] [18] [19] We have recently described measures that led to reduction of DNT in the Helsinki Center, 20, 21 where the current median DNT is 20 minutes. In the Barnes-Jewish Hospital in St. Louis, reduction of DNT was achieved after implementation of value stream analysis of Toyota's lean manufacturing principles. 22 In this study, we observed that DNT was associated with annual volume of patients, sex, history of hypertension and previous stroke, and baseline NIHSS, findings similar to Get With The Guidelines. 9 In another analysis of Get With The Guidelines, Xian et al 23 reported 3 hospital strategies independently associated with lower DNT: rapid triage/stroke team notification, single-call activation system, and tissue-type plasminogen activator stored in the emergency department.
Results of the study presented here suggest that learning and experience in delivering thrombolysis in a timely fashion are transferrable. Also, many centers have made little progress in reducing DNT during the past 10 years. On the basis of these findings, we decided to launch a global project aiming to reduce DNT: Reduction of In-hospital Delays in Stroke Thrombolysis (SITS-WATCH). In the pilot phase of the project, we sent an itemized questionnaire to the SITS centers. This pilot phase helped us to understand the local situation and to recognize the factors prolonging DNT in the SITS centers. In the next phase, we sent specific tasks to the participating centers, via implementation of which it is possible to reduce DNT. Clearly, factors like rural versus urban, academic versus community-based, public versus private settings, availability of neurological and radiological expertise, level of emergency medical services expertise, prenotification, and many others do most probably play a role. The SITS-WATCH project is registered under its name at http://www.clinicaltrials.gov (NCT01811901). A similar initiative Target: Stroke is organized by the American Heart Association/American Stroke Association. 24 Our study has limitations. We did not extract safety data (symptomatic intracranial hemorrhage) for the purpose of this study. However, safety data were described in other SITS publications. 25 In the Helsinki center, the continuous decline in DNT was achieved without an increase in the rate of hemorrhagic complications. 20 Furthermore, we do not present any outcome data, as relationship between shorter treatment delays and better functional outcome was addressed elsewhere. 1, 3, 4 Our data come mostly from European centers, which is an important issue on generalizability of our findings to other countries with varying systems of stroke care. Last but not least, the SITS registry includes patients based on voluntary registration of participating centers, which might have caused a selection/referral bias. To conclude, only minor overall improvements in DNT were observed during the first decade of the SITS registry. About experience, center volume is more important than the year of treatment. Hence, a multicenter project to reduce DNT focusing mostly on the centers with lower annual volume is warranted. We think such a project is feasible. As an example, the Helsinki experience was used in the Melbourne center, where the in-hours median DNT dropped from 43 (33-59) minutes to 25 (19-48) minutes in 4 months after implementation of the changes. 26 Because Melbourne is a single and a dedicated stroke center and we do not have the data on DNT in centers not participating in the SITS, we cannot anticipate that DNT would fall to such low levels in other centers. Substantial changes can nonetheless be achieved. 
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